RX 108Alternative Names: RX108
Latest Information Update: 10 Jun 2015
At a glance
- Originator Suzhou NeuPharma
- Developer Suzhou NeuPharma; University of Western Sydney
- Class Antineoplastics; Small molecules; Steroids
- Mechanism of Action Sodium-potassium-chloride symporter inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours